Eph A8 Activators
Eph A8 activators encompass a variety of chemical compounds that indirectly augment the functional activity of Eph A8 by modulating diverse signaling pathways. Anisomycin, for instance, stimulates stress-activated protein kinases that can phosphorylate downstream targets, potentially enhancing Eph A8 kinase activity which is crucial forneuronal development and plasticity. Similarly, 8-Bromo-cAMP, by boosting PKA activity, can enhance the phosphorylation of substrates that interact with Eph A8, facilitating its role in neuroplasticity. The modulation of intracellular calcium through Bay K8644 could indirectly potentiate Eph A8's involvement in neuronal growth cone guidance by activating calcium-dependent pathways. Bisindolylmaleimide I and Y-27632 subtly shift the balance of intracellular signaling, potentially enriching Eph A8-mediated pathways in cell morphology and central nervous system development by inhibiting PKC and ROCK, respectively. PP2 and U0126, by inhibiting Src family kinases and the MAPK/ERK pathway, may bolster Eph A8's role in axon guidance and synaptic plasticity. Inhibition of focal adhesion kinase by PF-562271 could similarly enhance Eph A8 signaling integral to cell adhesion and movement.
Further, compounds like Wiskostatin and NSC 23766 alter the dynamics of actin and the activity of Rac1, respectively, which could amplify Eph A8-mediated signaling in neuronal growth cone dynamics and spine morphogenesis. GSK2334470's inhibition of PDK1 is thought to enhance Eph A8 pathways involved in neuronal guidance, as PDK1 regulates multiple downstream kinases that could intersect with Eph A8 signaling. N,N-Dimethylsphingosine, by affecting sphingosine kinase activity, intersects with S1P receptor signaling, potentially influencing pathways that Eph A8 is part of, which govern cell migration and adhesion. These chemicals, through their targeted modulation of various cellular signaling cascades, collectively contribute to the functional enhancement of Eph A8, a protein involved in critical processes such as cell migration, adhesion, and neurodevelopment.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a protein synthesis inhibitor known to activate stress-activated protein kinases (SAPKs/JNKs), leading to the phosphorylation of various downstream targets, including Eph receptors which could enhance Eph A8's kinase activity. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that activates PKA. PKA activation can phosphorylate substrates that interact with Eph A8, potentially enhancing its role in neuroplasticity and neural development processes. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $82.00 $192.00 $801.00 | ||
Bay K8644 is an L-type calcium channel agonist. By increasing intracellular Ca2+ levels, it might indirectly activate signaling pathways that lead to the activation of Eph A8, which is involved in neuronal growth cone guidance. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
This compound is a specific inhibitor of PKC. Inhibition of PKC can shift the balance of intracellular signaling, potentially enhancing alternative pathways including those mediated by Eph A8 in neuronal development and synaptic plasticity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK kinase. Inhibition of ROCK can lead to actin cytoskeleton rearrangements, influencing Eph A8-related pathways in cell morphology and nervous system development. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting competitive signaling pathways, PP2 may enhance signaling cascades involving Eph A8 in axon guidance and synaptic plasticity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are involved in the MAPK/ERK pathway. By modulating this pathway, U0126 may indirectly enhance Eph A8 signaling mechanisms in cell migration and differentiation processes. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $306.00 $465.00 $1102.00 | 3 | |
PF-562271 is a potent inhibitor of focal adhesion kinase (FAK). Inhibition of FAK can enhance Eph A8 signaling, which is integral to cell adhesion and movement, as it could reduce competitive signaling through integrins. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
Wiskostatin is an inhibitor of the actin-regulating protein N-WASP. Modulation of actin dynamics by Wiskostatin can enhance Eph A8-mediated signaling in neuronal growth cone dynamics and spine morphogenesis. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
NSC 23766 is an inhibitor of Rac1 activation. By selectively inhibiting Rac1, it may enhance Eph A8's role in growth cone collapse and cell repulsion by modulating the signaling pathways involved in these processes. | ||||||